Form 10-Q · Quarterly report
Viatris 10-Q, filed Nov 5, 2026
- Filed
- CIK
- 0001792044
- Accession no.
- 0001792044-26-000057
Summary
Viatris filed its quarterly report for the period ended September 30, 2026, covering its business, four reportable segments, strategic initiatives, and risks including uncertainty over completing its proposed acquisition of Pacira and realizing its anticipated benefits.
Key points
- Viatris operates in more than 165 countries and territories with approximately 30,000 employees and 27 manufacturing, packaging, and distribution sites.
- Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
- Viatris supplies medicines to approximately 1 billion patients annually.
- Viatris cited risks that it may not complete its proposed acquisition of Pacira within its anticipated timeframe or realize the anticipated benefits.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis addresses material changes in the financial condition and results of operations of Viatris Inc. and subsidiaries for the periods presented. Unless context requires otherwise, the “Company,” “Viatris,” “our” or “we” refer to Viatris Inc. and its subsidiaries. This discussion and analysis should be read in conjunction with the Consolidated Financial Statements, the related Notes to Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Viatris’ 2025 Form 10-K, the unaudited interim…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.